GSK3B and early-onset autosomal dominant Alzheimer disease: Another study [18] described that EGCG disrupts amyloid-beta aggregation in Alzheimer’s disease, enhances protective α-helix structures, and modulates critical neuronal pathways such as GSK3-β and PI3K/Akt to reduce oxidative stress.